FibroX Therapeutics

FibroX Therapeutics is a Shanghai-based biotechnology company specializing in the development of innovative cell therapies for degenerative musculoskeletal diseases. The company's proprietary platform leverages allogeneic human dermal fibroblasts to promote tissue repair, reduce inflammation, and restore structural stability. Its lead candidate, FibroCell-001 (an allogeneic human fibroblast injection), is currently in Phase 1/2 clinical development for the treatment of moderate-to-severe lumbar disc degenerative disease. FibroX Therapeutics is also expanding its pipeline to target other high-unmet-need indications, including rotator cuff injuries, ligament damage, and senile refractory fractures.